<http://webisa.webdatacommons.org/448075774>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/448075774>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<freshpatents.com> .
<http://webisa.webdatacommons.org/prov/361083863>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/448075774> .
<http://webisa.webdatacommons.org/448075774>	<http://www.w3.org/ns/prov#value>	"In general, specific binding agents such as antibodies, antibody fragments, peptibodies, avimers, or Fc-peptide fusions, that specifically bind and inhibit Tie2, Ang2, or Ang1 and Ang2 polypeptides are within the scope of the present invention." .